Malignant Glioma
Conditions
Keywords
Malignant glioma, Glioblastoma multiforme, GBM, Gliosarcoma, Anaplastic astrocytoma, Brain cancer, Brain tumor, Glioma, recurrent/progressive malignant glioma
Brief summary
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma. This study is a two stage phase 1 study, in which a de-escalating dosing scheme will be used, i.e. the first patients will receive the higher dose and if excessive toxicity occurs, the dose will be reduced for the following patients. The purpose of the dose de-escalation phase is to find the best safe dose of G207. In the first stage of the study, treatment with G207 will be followed by focal radiation therapy on the following day, and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day. All patients will return to the clinic 28 days and 3, 6, 9 and 12 months after G207 administration at which time clinical assessments will be performed, and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter.
Interventions
DRUGG207
1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
Sponsors
National Cancer Institute (NCI)
MediGene
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pathologically proven residual/recurrent glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma which is progressive despite radiotherapy or chemotherapy 2. Failed external beam radiotherapy \> 5,000 CGy at least 4 weeks prior to enrollment 3. Residual/recurrent lesion must be ≥ 1.0 cm and (for Stage 2 only) ≤ 4 cm in diameter as determined by magnetic resonance imaging (MRI) 4. Normal hematological, renal and liver function * Absolute neutrophil count \> 1500/mm3 * Platelets \> 100,000/mm3 * Prothrombin time (PT) or partial thromboplastin time (PTT) \< 1.3 x control * Creatinine \< 1.7 mg/dl * Total bilirubin \< 1.5 mg/dl * Transaminases \< 4 times above the upper limits of the institutional norm 5. Karnofsky Performance Status score ≥ 70 6. Age \> 19 years-old 7. Capable of giving informed consent 8. Must be willing to practice an effective barrier method of birth control for 2 months post G207 inoculation, whether male or female 9. Females of childbearing potential: negative pregnancy test within 24 hours prior to G207 administration
Exclusion criteria
1. Surgical resection within 4 weeks of enrolment 2. Acute infection, granulocytopenia or medical condition precluding surgery 3. Pregnant or lactating females 4. History of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection 5. Tumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatment or tumor involving both hemispheres or with subependymal/cerebral spinal fluid (CSF) dissemination 6. Tumor position that could, in the Investigator's opinion, pose the risk of penetration of the cerebral ventricular system during inoculation with the study drug (Note: If penetration of the ventricular system is suspected or confirmed, G207 administration must be aborted.) 7. Tumor locations that would expose the patient to unacceptable risk with radiation therapy 8. Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpesvirus protocol) 9. Prior participant in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment 10. Required steroid increase within 2 weeks prior to injection 11. HIV seropositive 12. Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir) 13. Active oral or genital herpes lesion 14. Any contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc. 15. Radiation treatment volume of greater than 4 cm maximum diameter (Stage 2 only)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | from 1st dose to end of study visit |
Secondary
| Measure | Time frame |
|---|---|
| Radiographic response | Withdrawal or death of last patient |
| Performance scale | Last patient out |
| Overall survival | Withdrawal or death of last patient |
| Immune response | Last patient out |
| Presence of G207 in blood and saliva | Last patient out |
Countries
United States
Outcome results
None listed